UMIN000032031.

Trial name or title	The steroid internal use method for patients with IgA nephropathy
Methods	Parallel RCT
Participants	Setting: not yet available Country: Japan Patients with biopsy‐proven IgAN (at least 20 years old) and with indication with steroid therapy Number: estimated 100 participants Mean age ± SD (years): not yet available Sex (M/F): not yet available Exclusion criteria: patients decided by the doctor to be unsuitable to use the study other than above
Interventions	Treatment group 1 Prednisolone: 0.5 mg/kg/day Treatment group 2 Prednisolone: 0.25 mg/kg/day
Outcomes	Safety Efficacy Adverse events
Starting date	April 2018
Contact information	Hitoshi Suzuki 03‐5802‐1065 shitoshi@juntendo.ac.jp
Notes	Estimated study completion date: not yet available No study results available

ACEi ‐ angiotensin‐converting enzyme inhibitor; AKI ‐ acute kidney injury; ARB ‐ angiotensin receptor blocker; AZA ‐ azathioprine; BMI ‐ body mass index; BP ‐ blood pressure; CKD‐EPI ‐ Chronic Kidney Disease Epidemiology Collaboration; CPA ‐ cyclophosphamide; CrCl ‐ creatinine clearance; CSA ‐ cyclosporin; DBP ‐ diastolic blood pressure; DM ‐ diabetes mellitus; ESKD ‐ end‐stage kidney disease; (e)GFR ‐ (estimated) glomerular filtration rate; GN ‐ glomerulonephritis; HCT ‐ hematocrit; HIV ‐ human immunodeficiency virus; HSP ‐ Henoch‐Schönlein purpura; IgAN ‐ IgA nephropathy; KRT ‐ kidney replacement therapy; M/F ‐ male/female; MDRD ‐ Modified Diet in Renal Disease; MMF ‐ mycophenolate mofetil; PRA ‐ panel reactive antibody; RAS ‐ renin‐angiotensin system; RCT ‐ randomised controlled trial; SBP ‐ systemic blood pressure; SC ‐ subcutaneous; SCr ‐ serum creatinine; SD ‐ standard deviation; SLE ‐ systemic lupus erythematosus; TB ‐ tuberculosis; WBC ‐ white blood cell count; UPCR ‐ urinary protein:creatinine ratio